Second act! Cinven & Bain launched their final tender offer on the remaining listed shares of Stada, a leading German-based drugmaker, finally valuing the business at over €6bn

By Ricardo Mühle, Felix Paul Schäfer and Massimiliano Marchisio Date October 1st 2018 Type of transaction Public delisting tender offer Valuation 15-15.5x LTM 2018 June EBITDA of c. €410m Bidder Cinven-Bain Capital consortium Target company (sector) Financials STADA AG, “STADA” (Medical – Pharmaceuticals) FY17 Rev. / EBITDA: €2.3bn / €0.4bn (17.4% margin) Advisors (first bid)Continue reading “Second act! Cinven & Bain launched their final tender offer on the remaining listed shares of Stada, a leading German-based drugmaker, finally valuing the business at over €6bn”